Post COVID-19, the pharmaceutical cold chain players have made consistent strides towards making themselves more adept to the requirements of modern medicines.
Be it artificial intelligence or blockchain technology, innovations to keep pharmaceutical packaging upbeat and upgraded have begun to take the centre stage.
Although tech firms focus on revenues from technology license and pharma firms depend on blockbuster drugs, their ties can help in better industry innovation.
Amidst suing U.S. Department of Health and Human Services, which controls the medicare, drugmakers have gone on to call the price setting as unconstitutional.
The Swedish Association has raised concerns that are related to pricing as well as equal access to medicines and treatments throughout EU member countries.
